COVID vax makers finally study long-term heart damage as FDA admits bivalent data lacking
HHS corrects stats on tripling of COVID-related pediatric hospitalizations, used to justify booster campaign for kids, after analyst calls out bad data. CNN still hasn't corrected false report.
The Facts Inside Our Reporter’s Notebook
- FDA added heart inflammation warnings
- campus vaccine mandates on a demographic at higher risk
- NBC News
- It started contacting people in late September
- post-vaccination "emergency" heart problems in 16-39 year-olds
- Nature journal that published it added an ominous "editor's note"
- Journal of the American College of Cardiology study
- earlier research reviewed
- new preprint
- The New York Times
- no improvement over original boosters
- National Institutes of Health Director Lawrence Tabak
- as-yet uncorrected CNN report
- CDC figures through Nov. 16
- Pfizer's selective disclosure of trial data
- press release Nov. 14
- knocked out by BQ.1 and BQ.1.1
- Pfizer and its partner BioNTech
More than a year after the FDA added heart inflammation warnings to COVID-19 mRNA vaccines — amid the second academic year of campus vaccine mandates on a demographic at higher risk of severe adverse events — vaccine makers are finally studying the long-term consequences of vaccine-induced myocarditis and pericarditis.
Moderna already has two trials running, while Pfizer said its first trial will start "in the next couple months" and include up to 500 teenagers and young adults under 21, NBC News reported last week. Neither has disclosed the studies on their websites.
The CDC isn't much further ahead in studying long-term post-vaccination harm. In late September, the agency started contacting people who meet the case definition of myocarditis and have been reported to the Vaccine Adverse Events Reporting System.
While an "independent entity" should be reviewing long-term consequences, it's "puzzling" why Pfizer and Moderna waited so long to follow through on the FDA's approval conditions, said MIT professor Retsef Levi, lead author of a study on post-vaccination "emergency" heart problems in 16-39 year-olds in highly vaccinated Israel.
His paper remains in reputational limbo more than six months after the Nature journal that published it added an ominous "editor's note" promising an investigation of criticisms.
"This paper is still under investigation and we are carefully considering all the information and ... possible courses of action the editors could take to ensure the scientific record is maintained," Scientific Reports chief editor Rafal Marszalek wrote in a statement given to Just the News.
The vaccine makers' belated research follows research that finds heart inflammation is two to three times more likely following second doses of Moderna than Pfizer.
The Journal of the American College of Cardiology study by Canadian researchers, which used the British Columbia COVID-19 cohort, found the strongest association with men and people 18-39 years old. This echoes earlier research reviewed by the CDC's Advisory Committee on Immunization Practices.
Pfizer's new bivalent booster — like Moderna's, composed of now-outdated Omicron BA.4/5 subvariants and Wuhan strain — is also under scrutiny.
It has much higher rates of side effects than its original booster, according to a new preprint by University Hospital Wuerzburg researchers and an Oxford researcher who "receives honoraria" from Pfizer.
Their non-randomized controlled study of 76 healthcare workers who took a fourth dose, not yet peer-reviewed, showed the bivalent recipients had an 85% adverse-event rate, contrasted with 51% for the monovalent. The bivalent was also followed by "an increased rate of inability to work and intake of PRN [as needed] medication."
The FDA's vaccines chief recently admitted how little data the agency has to justify its enthusiasm for bivalent boosters.
Center for Biologics Evaluation and Research Director Peter Marks told The New York Times "we're not sure how well these vaccines will do yet against preventing symptomatic disease," particularly from newer subvariants.
But he claimed "the downside is pretty low" to getting the new jabs in relation to the "positive consequences" that would follow "even modest improvements in vaccine response."
Weill Cornell Medicine virologist John Moore questioned the government strategy of "chasing variants by tweaking" the vaccine composition, telling the Times not to expect "amazing protection pagainst infection" from them.
The FDA didn't answer Just the News queries for the evidence Marks used to make his claims, given the bivalent boosters weren't tested in humans and their makers are only now following up on possible long-term damage from the original vaccines.
Outside studies thus far have shown no improvement over original boosters, and National Institutes of Health Director Lawrence Tabak recently cited "hope," not evidence, that bivalents "will offer even broader protection."
The feds' longstanding efforts to play down post-vaccination heart problems stand in contrast to their urgent appeals to boost young children, backed by data revealed to be false.
The Department of Health and Human Services admitted the goof on COVID-related pediatric hospitalizations, which inexplicably tripled on paper this month, after an eagle-eyed COVID analyst notified HHS of an implausible week-to-week jump in Florida that skewed the entire country.
The false stats were cited in an as-yet uncorrected CNN report on a Yale School of Public Health model predicting that a 50-60% booster rate could prevent at least 38,000 pediatric hospitalizations. Fewer than 5% of kids 5-11 have received a bivalent booster, and every age group under 65 is below 20%, according to CDC figures through Nov. 16.
Copying Pfizer's selective disclosure of trial data from its bivalent, Moderna issued a press release Nov. 14 claiming both of its bivalent candidates "trigger a superior antibody response" relative to its original against Omicron BA.4/5, which has already been knocked out by BQ.1 and BQ.1.1.
CEO Stephane Bancel said this response — five times greater than the original — "persisted for at least three months" and showed "neutralizing activity against BQ.1.1," illustrating the "potential to offer protection" against evolving variants. The study of boosted individuals didn't include anyone under age 19.
Pfizer and its partner BioNTech said Wednesday they've started a Phase I study to test a "next generation" vaccine that enhances long-term T-cell response, as opposed to fast-waning antibody jumps, by encoding for "non-spike proteins that are highly conserved" across variants. The trial will be limited to "healthy," boosted 18-55 year-olds.